Loading…
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $106M | $99M | $83M | $-2M | 53.8% | 350.9% | - |
| 2024 | $24M | $-76M | $-106M | $-70M | -266.0% | -14.0% | - |
| 2023 | $27M | $-44M | $-46M | $-34M | -74.4% | 170.3% | - |
| 2022 | $10M | $-26M | $-27M | $-19M | -35.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 10.16 | 27.46 | 23.61 | 106.47 |
| Cost Of Revenue | 0.22 | 2.17 | 7.42 | 16.48 |
| Gross Profit | 9.94 | 25.29 | 16.20 | 89.99 |
| Operating Expense | 34.84 | 74.89 | 103.20 | 94.22 |
| Operating Income | -24.90 | -49.60 | -87 | -4.23 |
| EBITDA | -25.53 | -43.54 | -76.40 | 98.71 |
| EBIT | -26.47 | -44.55 | -82.79 | 94.66 |
| Pretax Income | -26.80 | -46.05 | -90.14 | 86.68 |
| Tax Provision | -0.03 | 0 | 15.37 | 3.45 |
| Net Income | -26.77 | -46.05 | -105.51 | 83.23 |
| Net Income Common Stockholders | -26.77 | -46.05 | -105.51 | 83.23 |
| Total Expenses | 35.06 | 77.06 | 110.61 | 110.70 |
| Interest Expense | 0.34 | 1.50 | 7.35 | 7.98 |
| Interest Income | 1.51 | 4.54 | 2.17 | 6.95 |
| Research And Development | 19.80 | 39.81 | 42.09 | 12.74 |
| Selling General And Administration | 15.04 | 34.31 | 54.87 | 77.62 |
| Normalized EBITDA | -22.45 | -44.06 | -78.44 | 6.77 |
| Normalized Income | -23.69 | -46.56 | -107.12 | -5.05 |
| Basic EPS | -1.20 | -1.30 | -2.28 | 1.40 |
| Diluted EPS | -1.20 | -1.30 | -2.28 | 1.35 |
| Tax Effect Of Unusual Items | 0 | 0 | 0.43 | 3.66 |
| Tax Rate For Calcs | 0 | 0 | 0.21 | 0.04 |
| Total Unusual Items | -3.08 | 0.52 | 2.04 | 91.94 |
| Total Unusual Items Excluding Goodwill | -3.08 | 0.52 | 2.04 | 91.94 |
| Net Income From Continuing Operation Net Minority Interest | -26.77 | -46.05 | -105.51 | 83.23 |
| Reconciled Depreciation | 0.94 | 1.01 | 6.39 | 4.05 |
| Reconciled Cost Of Revenue | 0.22 | 1.94 | 7.26 | 16.29 |
| Net Interest Income | 1.18 | 3.04 | -5.18 | -1.03 |
| Net Income From Continuing And Discontinued Operation | -26.77 | -46.05 | -105.51 | 83.23 |
| Total Operating Income As Reported | -42.56 | -49.60 | -87 | -62.94 |
| Diluted Average Shares | 34.49 | 35.45 | 46.25 | 57.26 |
| Basic Average Shares | 34.49 | 35.45 | 46.25 | 55.31 |
| Diluted NI Availto Com Stockholders | -26.77 | -46.05 | -105.51 | 83.23 |
| Otherunder Preferred Stock Dividend | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -26.77 | -46.05 | -105.51 | 83.23 |
| Net Income Continuous Operations | -26.77 | -46.05 | -105.51 | 83.23 |
| Other Income Expense | -3.08 | 0.52 | 2.04 | 91.94 |
| Special Income Charges | -17.66 | 0 | 0 | 89.61 |
| Gain On Sale Of Ppe | 0 | 0 | 0 | 148.32 |
| Other Special Charges | 17.66 | 0 | 0 | 0 |
| Impairment Of Capital Assets | 0 | 0 | 0 | 58.71 |
| Restructuring And Mergern Acquisition | 0 | 0 | 0 | 0 |
| Gain On Sale Of Security | 14.58 | 0.52 | 2.04 | 2.33 |
| Net Non Operating Interest Income Expense | 1.18 | 3.04 | -5.18 | -1.03 |
| Total Other Finance Cost | 0 | 0 | 0 | 0 |
| Interest Expense Non Operating | 0.34 | 1.50 | 7.35 | 7.98 |
| Interest Income Non Operating | 1.51 | 4.54 | 2.17 | 6.95 |
| Depreciation Amortization Depletion Income Statement | 0 | 0.77 | 6.24 | 3.86 |
| Depreciation And Amortization In Income Statement | 0 | 0.77 | 6.24 | 3.86 |
| Amortization | 0 | 0.77 | 6.24 | 3.86 |
| Amortization Of Intangibles Income Statement | 0 | 0.77 | 6.24 | 3.86 |
| General And Administrative Expense | 15.34 | 0 | 0 | 0 |
| Other Gand A | 15.34 | 0 | 0 | 0 |
| Operating Revenue | 10.16 | 27.46 | 23.61 | 106.47 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Zevra Therapeutics, Inc.this co. | ZVRA | $572M | 7.16↑ premium | 3.56 | 53.8% | -2457.74 |
| CorMedix Inc. | CRMD | $591M | 3.67 | 1.46 | 40.2% | 3.38 |
| Prothena Corporation plc | PRTA | $585M | - | 2.09 | -87.0% | -1.56 |
| Anteris Technologies Global Corp. | AVR | $574M | - | -2950.00 | - | -6.11 |
| Phreesia, Inc. | PHR | $569M |
| 234.25 |
| 1.69 |
| 0.7% |
| 29.02 |
| NeuroPace, Inc. | NPCE | $562M | - | 29.17 | -112.8% | -35.19 |
| Rigel Pharmaceuticals, Inc. | RIGL | $540M | 1.50 | 1.37 | 93.8% | 3.43 |
| Embecta Corp. | EMBC | $536M | 5.72 | -0.84 | -14.6% | 6.16 |
| SI-BONE, Inc. | SIBN | $528M | - | 2.93 | -10.6% | -25.11 |
| Peer Median | - | 4.70 | 1.57 | -10.6% | 0.91 | |